Dual biologic therapy may serve as a suitable treatment choice for patients with IBD who have not responded to current therapies.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Analysts have suggested that TL1A inhibitors could have blockbuster sales potential as second-line therapy for IBD refractory to first-line TNF biologics, with plenty of upside if they move into ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Physical therapy stock Encompass Health is in a base awaiting a catalyst for its next move. The company's profit grew 23% in ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day treatment for inflammatory bowel disease (IBD). The presentation ...

Mental health comorbidities are more prevalent among transgender and gender nonconforming adults with IBD than the general and IBD US populations.

In a US study, researchers found that 35% of adults with IBD screened positive for spondyloarthritis, despite having no known SpA diagnosis.

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...